Xiaowei Ren

1 works

Takeda Development Center Americas, Inc., Lexington, USA

1. POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial

   Jane F. Apperley, Jörge E. Cortes, Elias Jabbour +21

   ArticleChronic Myeloid Leukemia TreatmentsClinical Lymphoma Myeloma & Leukemia20230 citations

   ABIABI:AkademIndex/openalex/2023.article.010140